KURE.L vs. BTEE.L

Last updated Jun 5, 2026

KURE.L (KraneShares MSCI All China Health Care Index UCITS ETF USD) and BTEE.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) are both Health & Biotech Equities funds - KURE.L tracks the MSCI World/Health Care NR USD while BTEE.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past year, KURE.L returned -10.89% vs 41.45% for BTEE.L. At a 0.32 correlation, their price movements are largely independent. KURE.L charges 0.65%/yr vs 0.35%/yr for BTEE.L.

Performance

KURE.L vs. BTEE.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KURE.L achieves a -10.68% return, which is significantly lower than BTEE.L's 4.58% return.

KURE.L

• 1D: -2.87%
• 1M: -12.38%
• YTD: -10.68%
• 6M: -19.51%
• 1Y: -10.89%
• 3Y*: —
• 5Y*: —
• 10Y*: —

BTEE.L

• 1D: 3.30%
• 1M: 1.17%
• YTD: 4.58%
• 6M: 3.18%
• 1Y: 41.45%
• 3Y*: 13.12%
• 5Y*: 4.70%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

KURE.L vs. BTEE.L - Yearly Performance Comparison

	2026 (YTD)	2025
KURE.L KraneShares MSCI All China Health Care Index UCITS ETF USD	-10.68%	11.52%
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	4.58%	37.42%

Correlation

The correlation between KURE.L and BTEE.L is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.31
Correlation (All Time) Calculated using the full available price history since Apr 29, 2025	0.32

KURE.L vs. BTEE.L - Sectors Allocation Comparison

Sectors	KURE.L	BTEE.L
Healthcare	98.3%	100.0%
Consumer Defensive	0.9%	-
Basic Materials	0.8%	-
Communication Services	0.0%	-
Consumer Cyclical	0.0%	-
Energy	0.0%	-
Financial Services	0.0%	-
Industrials	0.0%	-
Real Estate	0.0%	-
Technology	0.0%	-
Utilities	0.0%	-

Return for Risk

KURE.L vs. BTEE.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KURE.L

KURE.L Risk / Return Rank: 6
KURE.L Sharpe Ratio Rank: 6
KURE.L Sortino Ratio Rank: 6
KURE.L Omega Ratio Rank: 6
KURE.L Calmar Ratio Rank: 6
KURE.L Martin Ratio Rank: 6

BTEE.L

BTEE.L Risk / Return Rank: 72
BTEE.L Sharpe Ratio Rank: 64
BTEE.L Sortino Ratio Rank: 66
BTEE.L Omega Ratio Rank: 57
BTEE.L Calmar Ratio Rank: 89
BTEE.L Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KURE.L vs. BTEE.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KURE.L	BTEE.L	Difference
Sharpe ratio: Return per unit of total volatility	-0.33	2.10	-2.43
Sortino ratio: Return per unit of downside risk	-0.28	3.01	-3.29
Omega ratio: Gain probability vs. loss probability	0.97	1.35	-0.38
Calmar ratio: Return relative to maximum drawdown	-0.29	5.41	-5.70
Martin ratio: Return relative to average drawdown	-0.58	16.70	-17.28
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KURE.L vs. BTEE.L - Sharpe Ratio Comparison

The current KURE.L Sharpe Ratio is -0.33, which is lower than the BTEE.L Sharpe Ratio of 2.10. The chart below compares the historical Sharpe Ratios of KURE.L and BTEE.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	KURE.L	BTEE.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.33	2.10	-2.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.22	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.30	-0.32

Drawdowns

KURE.L vs. BTEE.L - Drawdown Comparison

The maximum KURE.L drawdown since its inception was -30.31%, smaller than the maximum BTEE.L drawdown of -38.29%. Use the drawdown chart below to compare losses from any high point for KURE.L and BTEE.L.

Drawdown Indicators

	KURE.L	BTEE.L	Difference
Max Drawdown Largest peak-to-trough decline	-30.31%	-38.29%	+7.98%
Max Drawdown (1Y) Largest decline over 1 year	-30.31%	-7.63%	-22.68%
Max Drawdown (3Y) Largest decline over 3 years	—	-26.82%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-38.29%	—
Current Drawdown Current decline from peak	-30.31%	-2.58%	-27.73%
Average Drawdown Average peak-to-trough decline	-11.49%	-13.56%	+2.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.98%	2.47%	+12.51%

Volatility

KURE.L vs. BTEE.L - Volatility Comparison

KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) has a higher volatility of 7.23% compared to iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) at 6.84%. This indicates that KURE.L's price experiences larger fluctuations and is considered to be riskier than BTEE.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KURE.L	BTEE.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.23%	6.84%	+0.39%
Volatility (6M) Calculated over the trailing 6-month period	18.31%	15.33%	+2.98%
Volatility (1Y) Calculated over the trailing 1-year period	26.92%	19.63%	+7.29%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.64%	21.14%	+5.50%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.64%	22.50%	+4.14%

KURE.L vs. BTEE.L - Expense Ratio Comparison

KURE.L has a 0.65% expense ratio, which is higher than BTEE.L's 0.35% expense ratio.

Dividends

KURE.L vs. BTEE.L - Dividend Comparison

KURE.L has not paid dividends to shareholders, while BTEE.L's dividend yield for the trailing twelve months is around 0.36%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.36%	0.37%	0.46%	0.39%	0.44%	0.25%	0.17%	0.14%	0.07%
KURE.L KraneShares MSCI All China Health Care Index UCITS ETF USD	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both KURE.L and BTEE.L in my portfolio?

KURE.L and BTEE.L have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, KURE.L or BTEE.L?

On fees, BTEE.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, KURE.L or BTEE.L?

BTEE.L is cheaper with a 0.35% expense ratio, compared with 0.65% for KURE.L.

What is the main difference between KURE.L and BTEE.L?

KURE.L tracks MSCI World/Health Care NR USD, while BTEE.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: MLC Management and iShares. Their fees differ too: 0.65% for KURE.L and 0.35% for BTEE.L.